Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

LiT-Met Liver Transplantation for Colorectal Liver Metastases: An International Real-Life Analysis of Post-Transplant Outcomes (LiT-Met)

Coordinator
Alma Mater Studiorum - Universita Di Bologna, Italy
Runs
1 July 2026 to 30 June 2031
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
21 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101290423

What the project is doing

In the project's own words, from its summary on CORDIS.

Colorectal cancer is the third most common malignancy globally, with liver metastases responsible for over half of related deaths. While liver resection offers curative potential, long-term survival in borderline resectable cases remains poor. Liver transplantation (LT), once contraindicated for colorectal liver metastases (CRLM), has recently shown promising outcomes, with 5-year survival rates reaching 83% in selected patients.

The LiT-Met project aims to generate robust multicentre evidence demonstrating that LT provides superior survival compared to current surgical standards in borderline resectable CRLM. The ultimate goal is to develop pan-European evidence-based guidelines and adapt national allocation policies to ensure equitable access to life-prolonging therapies. To achieve this, LiT-Met will pursue six specific objectives: improve overall survival through prospective cohort studies and long-term follow-up; develop an AI-based prognostic model integrating clinical, pathological, and molecular data; perform comprehensive molecular profiling of tumors and circulating biomarkers; implement an AI-supported clinical decision system combining imaging and biomarkers; conduct a European-wide cost-effectiveness analysis comparing LT and resection; and integrate patient-reported outcomes and quality-of-life measures into clinical endpoints and policy recommendations.

These efforts will culminate in harmonized transplant eligibility criteria, improved patient selection, and enhanced survival and quality of life. By combining clinical, biological, economic, and societal dimensions, LiT-Met will catalyze a paradigm shift in transplant oncology across Europe. This action is part of the Cancer Mission cluster ofprojects on “Diagnosis and Treatment-Innovative Surgery

Topics

Who is involved

OrganisationCityCountryRole
Alma Mater Studiorum - Universita Di BolognaBolognaItalyCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
Medizinische Universitat InnsbruckInnsbruckAustriaParticipant
Centre Hospitalier Universitaire De LiegeLiegeBelgiumParticipant
European Cancer OrganisationBruxelles / BrusselBelgiumParticipant
Universitat ZurichZurichSwitzerlandParticipant
Institut klinické a experimentální medicinyPrague 4CzechiaParticipant
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Universitatsklinikum JenaJenaGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Wise Angle Consulting SLBarcelonaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Semmelweis EgyetemBudapestHungaryAssociatedpartner
Azienda Ospedaliera Citta Della Salute E Della Scienza Di TorinoTorinoItalyParticipant
Biolt SrlsRomaItalyParticipant
Irccs Azienda Ospedaliero- Universitaria Di BolognaBolognaItalyParticipant
Istituto Mediterraneo per I Trapianti E Terapie Ad Alta Specializzazione SRL - Ismett SRLPalermoItalyParticipant
University of Pittsburgh Medical Center Italy Srl(upmc Italy SRL)Palermo PaItalyThird party
European Society for Organ TransplantationAmsterdamNetherlandsParticipant
Unidade Local De Saude De Coimbra EpeCoimbraPortugalParticipant
King's College Hospital Nhs Foundation TrustLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI